Coherus Oncology (NASDAQ:CHRS) is a commercial-stage biopharmaceutical company focused on the development, manufacturing and commercialization of biologic therapies for oncology support and immuno-oncology. Founded in 2010 and headquartered in Redwood City, California, Coherus specializes in biosimilar versions of established oncology agents as well as novel immunotherapy candidates.
The company’s lead marketed products include Udenyca (pegfilgrastim-cbqv) and Fulphila (pegfilgrastim-jmdb), biosimilars to Amgen’s Neulasta, which are designed to reduce the incidence of infection in patients undergoing myelosuppressive chemotherapy. These pegfilgrastim biosimilars have received approval from the U.S. Food and Drug Administration and are distributed through a network of specialty pharmacies and wholesalers, supporting patients in the United States and select international markets.
Beyond supportive-care biologics, Coherus Oncology maintains a pipeline of immuno-oncology candidates, including anti-PD-1 and anti-CTLA-4 monoclonal antibodies in clinical development. The company’s research and development efforts are aimed at advancing therapies for melanoma, non-small cell lung cancer and other solid tumors, with partnerships and licensing agreements that extend its global reach and facilitate late-stage clinical trials across North America, Europe and Asia.
Coherus operates its own manufacturing facilities to support both development and commercial supply, ensuring scalable production capabilities. Richard E. Fair serves as President and Chief Executive Officer, leading a management team with deep expertise in biologics development and oncology commercialization. Under this leadership, Coherus continues to expand its product portfolio and broaden patient access to high-quality oncology therapies.
